Comprehensive Review on Phytochemistry, Ethnobotanical, Bioactivities and Medicinal Mysteries of Ougeinia oojeinensis (Roxb.) Hochr

Ashwani Tiwari, Atul Patel, Sarika Shrivastava, Sarita Karole, Usha Vishwakarma, Prakash Mishra

Pharmaceutical and Biosciences Journal(2020)

引用 1|浏览0
暂无评分
摘要
Various parts of plants such as leaf, stem, roots and barks were used as medicines in auyrveda, siddha, unani and homeopathic treatments. As only few studies are done on such plant, the purpose of this current review is to make accessible till date information on, botany, morphology, ecological biodiversity, therapeutic uses, phytochemistry and pharmacological activities on diverse parts of Ougeinia oojeinensis. This review was assembled using technical literature from electronic search engine such as Springerlink, BioMed Central, PubMed, Scopus, ScienceDirect, Scielo, Medline and Science domain. Supplementary texts were obtained from books, book chapters, dissertations, websites and other scientific publications. O. oojeinensis commonly known as Tinsa, is rich in secondary metabolites, which impart incredible medicinal uses to the plant. The active constituents extracted from O. oojeinensis are genistein, ougenin, dalbergioidin, kaempferol, lupeol, Ferreirin, neophellamuretin, orobol, wedelolactone, homoferririn isoflavanone and betulin etc. The uses of bark are astringent, acrid, cooling, stimulant, anti-inflammatory, constipating, anthelmintic, sudorific, depurative, urinary astringent, styptic, febrifuge and rejuvenating. The extract of the whole plant showed anti-inflammatory, hypotensive action, antioxidant activity, hepatoprotective, anthelmintic, hypoglycemic and wound healing activities. There is a need to isolate the active constituents, their biological test, experimental defense, molecular mechanisms and legalization of there therapeutic uses of O. oojeinensis. The gathered detail will be obliging to determine the study protocol for current drugs and Ayurvedic formulation extension in the remedial and luxury a variety of ailments. Clinical trials for the reported preclinical studies should be executed immediately to further validate the claims on humans.
更多
查看译文
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要